Pricing Log in Create free account

Celularity, Inc. (CELU) vs TransCode Therapeutics Inc. (RNAZ)

Celularity, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. Celularity, Inc. and TransCode Therapeutics Inc. are of similar size ($25.6M and $23.5M). TransCode Therapeutics Inc. has the higher net margin (0.00% vs −247.7%) and the higher return on invested capital (0.00% vs −462.8%). Across the 13 metrics below, TransCode Therapeutics Inc. leads on 7 and Celularity, Inc. on 6.

Valuation

Metric CELU RNAZ Biotechnology median
P/E n/m n/m 10.60
P/S 1.19 n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.11 0.66
EV/Sales 3.45 n/m 9.02
Earnings yield (222.37%) (3,354.19%) (32.88%)
Free cash flow yield (40.93%) (1,565.69%) (23.13%)

Profitability

Metric CELU RNAZ Biotechnology median
Gross margin 19.23% 0.00% 68.51%
Operating margin (264.27%) 0.00% 0.00%
Net margin (247.71%) 0.00% 0.00%
Free cash flow margin (47.80%) 0.00% 0.00%
Return on equity 151.53% 429.61% (51.96%)
Return on assets (42.72%) (58.12%) (46.06%)
Return on invested capital (462.77%) 0.00% 0.00%

Growth

Metric CELU RNAZ Biotechnology median
Revenue growth (TTM) (58.14%) — 6.76%
EPS growth (last fiscal year) (35.98%) 96.02% 29.88%
Revenue growth, 5-year CAGR 13.21% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CELU RNAZ Biotechnology median
Debt to equity (1.20) 0.00 0.00
Current ratio 0.11 1.97 4.97
Net debt to EBITDA (0.77) 0.64 1.01

Dividend

Metric CELU RNAZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CELU RNAZ Biotechnology median
Market cap 23.54m 25.57m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack